Case Report: Disseminated, rifampicin resistant Mycobacterium bovis (BCG) infection in an immunocompromised child [version 1; peer review: 2 approved]
Background: Bacillus Calmette–Guérin (BCG) is a live-attenuated vaccine used world-wide for prevention of tuberculosis disease. In some immunocompromised hosts it has the potential to cause disease. As with other members of the M. tuberculosis complex it has the potential for acquiring drug resistan...
Main Authors: | Simon B. Drysdale, Dominic F. Kelly, Marcus Morgan, Tim Peto, Derrick Crook, Philippa C. Matthews, Timothy M. Walker |
---|---|
Format: | Article |
Language: | English |
Published: |
Wellcome
2020-10-01
|
Series: | Wellcome Open Research |
Online Access: | https://wellcomeopenresearch.org/articles/5-242/v1 |
Similar Items
-
Case report: Disseminated, rifampicin resistant Mycobacterium bovis (BCG) infection in an immunocompromised child
by: Drysdale, SB, et al.
Published: (2020) -
Mechanisms of cell accumulation induced by Mycobacterium bovis BCG
by: Octávio Menezes-de-Lima-Júnior, et al.
Published: (1997-12-01) -
Superinfection with SARS-CoV-2 Has Deleterious Effects on Mycobacterium bovis BCG Immunity and Promotes Dissemination of Mycobacterium tuberculosis
by: Rachel E. Hildebrand, et al.
Published: (2022-10-01) -
Auxotrophic <i>Mycobacterium bovis</i> BCG: Updates and Perspectives
by: Odir Antônio Dellagostin, et al.
Published: (2022-05-01) -
Optimisation of <i>Mycobacterium bovis</i> BCG Fermentation and Storage Survival
by: Jordan Pascoe, et al.
Published: (2020-09-01)